home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 02/03/21

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will deli...
ALGS - Aligos Therapeutics (ALGS) Presents At 39th Annual JP Morgan Healthcare Conference - Slideshow

The following slide deck was published by Aligos Therapeutics, Inc. in conjunction with this event. For further details see: Aligos Therapeutics (ALGS) Presents At 39th Annual JP Morgan Healthcare Conference - Slideshow

ALGS - Aligos Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, P...

ALGS - Aligos Therapeutics Presents Update on Development of SARS-CoV-2 Therapeutic Candidate and Screening Method in Collaboration with KU Leuven at RespiDART & Emerging Viruses 2020

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered...
ALGS - Aligos enters into an agreement with Merck to discover and develop an oligonucleotide therapy for NASH

Aligos Therapeutics (ALGS) entered into an exclusive license and research collaboration agreement with Merck (MRK) to apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis target a...

ALGS - Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Merck an...

ALGS - Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD's The Liver Meeting Digital Experience(TM) 2020

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has deliv...
ALGS - Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that management will be pa...

ALGS - Aligos Therapeutics secures Euro1.8M grant to advance hepatitis B research

Aligos Therapeutics' (ALGS) Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship ((VLAIO)) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA). The support w...

ALGS - Aligos Therapeutics is awarded Euro1.8M VLAIO grant to advance chronic hepatitis B research

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that i...
Previous 10 Next 10